{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T15:51:23Z","timestamp":1782057083149,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The microtubule protein \u03b2III-tubulin is a prognostic, pro-survival, and chemoresistance factor in multiple malignancies, including pancreatic ductal adenocarcinoma (PDAC). However, the precise survival mechanisms controlled by \u03b2III-tubulin in cancer remain unknown. Here, we discovered a link between \u03b2III-tubulin and the activation of caspase 8-mediated extrinsic apoptosis. Silencing \u03b2III-tubulin in PDAC cells activated caspase 8, leading to decreased cell viability and growth both in vitro and in vivo. \u03b2III-tubulin knockdown also increased the sensitivity of PDAC cells to extrinsic cell death signals, including TNF-related apoptosis-inducing ligand (TRAIL), TNF\u03b1, and FasL. Furthermore, we demonstrated that \u03b2III-tubulin knockdown in PDAC cells, in the absence or presence of TRAIL, increased diffusion and clustering of the TRAIL death receptor DR5 at the cell membrane, inducing extrinsic apoptosis. Nanoparticle delivery of \u03b2III-tubulin siRNA to mouse PDAC tumours reduced tumour growth and increased responsiveness to TRAIL therapy. In patient-derived human PDAC explants, \u03b2III-tubulin silencing reduced tumour cell frequency and improved sensitivity to TRAIL. Finally, we showed that high \u03b2III-tubulin expression in the human PDAC stroma was independently prognostic for poor overall survival. Taken together, silencing \u03b2III-tubulin represents an innovative strategy to activate a suicide signal in PDAC cells and render them more sensitive to microenvironment- and chemotherapy-derived death signals.<\/jats:p>","DOI":"10.1038\/s41419-026-08657-6","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:07:33Z","timestamp":1777046853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u03b2III-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-1930","authenticated-orcid":false,"given":"George","family":"Sharbeen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kokkinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Schulstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvis","family":"Pandzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Youkhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Mistica C.","family":"Ignacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna S.","family":"Raina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koroush S.","family":"Haghighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gunawarman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3871-3829","authenticated-orcid":false,"given":"Marina","family":"Pajic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5228-0919","authenticated-orcid":false,"given":"Oliver S. M.","family":"Arkell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrella","family":"Gonzales-Aloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ishak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"Erkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5766-9141","authenticated-orcid":false,"given":"Jennifer P.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kavallaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0833-3128","authenticated-orcid":false,"given":"Peter W.","family":"Gunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1649-7712","authenticated-orcid":false,"given":"Edna C.","family":"Hardeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9447-1967","authenticated-orcid":false,"given":"Anthony J.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee M.","family":"Whan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Mawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omali","family":"Pitiyarachchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Australian Pancreatic Cancer Genome Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"McCarroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"8657_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"8657_CR2","doi-asserted-by":"crossref","unstructured":"Kokkinos J, Jensen A, Sharbeen G, McCarroll JA, Goldstein D, Haghighi KS, et al. Does the microenvironment hold the hidden key for functional precision medicine in pancreatic cancer? Cancers. 2021;13:2427.","DOI":"10.3390\/cancers13102427"},{"key":"8657_CR3","doi-asserted-by":"crossref","unstructured":"Kung HC, Zheng KW, Zimmerman JW, Zheng L. The tumour microenvironment in pancreatic cancer - new clinical challenges, but more opportunities. Nat Rev Clin Oncol. 2025;22:969\u2013995.","DOI":"10.1038\/s41571-025-01077-z"},{"key":"8657_CR4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.trecan.2019.09.010","volume":"5","author":"BA Pereira","year":"2019","unstructured":"Pereira BA, Vennin C, Papanicolaou M, Chambers CR, Herrmann D, Morton JP, et al. CAF subpopulations: a new reservoir of stromal targets in pancreatic cancer. Trends Cancer. 2019;5:724\u201341.","journal-title":"Trends Cancer"},{"key":"8657_CR5","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1172\/JCI119642","volume":"100","author":"M Kavallaris","year":"1997","unstructured":"Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Investig. 1997;100:1282\u201393.","journal-title":"J Clin Investig"},{"key":"8657_CR6","doi-asserted-by":"publisher","first-page":"101042831771216","DOI":"10.1177\/1010428317712166","volume":"39","author":"F Person","year":"2017","unstructured":"Person F, Wilczak W, Hube-Magg C, Burdelski C, Moller-Koop C, Simon R, et al. Prevalence of betaIII-tubulin (TUBB3) expression in human normal tissues and cancers. Tumour Biol. 2017;39:1010428317712166.","journal-title":"Tumour Biol"},{"key":"8657_CR7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/1078-0432.298.11.1","volume":"11","author":"S Mozzetti","year":"2005","unstructured":"Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res. 2005;11:298\u2013305.","journal-title":"Clin Cancer Res"},{"key":"8657_CR8","first-page":"7139","volume":"16","author":"D Hoflmayer","year":"2018","unstructured":"Hoflmayer D, Ozturk E, Schroeder C, Hube-Magg C, Blessin NC, Simon R, et al. High expression of class III beta-tubulin in upper gastrointestinal cancer types. Oncol Lett. 2018;16:7139\u201345.","journal-title":"Oncol Lett"},{"key":"8657_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.21873\/anticanres.13160","volume":"39","author":"S Oztop","year":"2019","unstructured":"Oztop S, Isik A, Guner G, Gurdal H, Karabulut E, Yilmaz E, et al. Class III beta-tubulin expression in colorectal neoplasms is a potential predictive biomarker for paclitaxel response. Anticancer Res. 2019;39:655\u201362.","journal-title":"Anticancer Res"},{"key":"8657_CR10","first-page":"1390","volume":"23","author":"Y Jia","year":"2018","unstructured":"Jia Y, Sun S, Gao X, Cui X. Expression levels of TUBB3, ERCC1 and P-gp in ovarian cancer tissues and adjacent normal tissues and their clinical significance. J BUON. 2018;23:1390\u20135.","journal-title":"J BUON"},{"key":"8657_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4251\/wjgo.v10.i10.351","volume":"10","author":"XQ Kong","year":"2018","unstructured":"Kong XQ, Huang YX, Li JL, Zhang XQ, Peng QQ, Tang LR, et al. Prognostic value of vascular endothelial growth factor receptor 1 and class III beta-tubulin in survival for non-metastatic rectal cancer. World J Gastrointest Oncol. 2018;10:351\u20139.","journal-title":"World J Gastrointest Oncol"},{"key":"8657_CR12","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.18632\/oncotarget.2946","volume":"6","author":"JA McCarroll","year":"2015","unstructured":"McCarroll JA, Sharbeen G, Liu J, Youkhana J, Goldstein D, McCarthy N, et al. \u03b2III-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget. 2015;6:2235\u201349.","journal-title":"Oncotarget"},{"key":"8657_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1365-2559.2007.02792.x","volume":"51","author":"KM Lee","year":"2007","unstructured":"Lee KM, Cao D, Itami A, Pour PM, Hruban RH, Maitra A, et al. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology. 2007;51:539\u201346.","journal-title":"Histopathology"},{"key":"8657_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.humpath.2018.01.009","volume":"74","author":"A Kato","year":"2018","unstructured":"Kato A, Naiki-Ito A, Naitoh I, Hayashi K, Nakazawa T, Shimizu S, et al. The absence of class III beta-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma. Hum Pathol. 2018;74:92\u201398.","journal-title":"Hum Pathol"},{"key":"8657_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1158\/0008-5472.CAN-14-2740","volume":"75","author":"JA McCarroll","year":"2015","unstructured":"McCarroll JA, Gan PP, Erlich RB, Liu M, Dwarte T, Sagnella SS, et al. TUBB3\/betaIII-tubulin acts through the PTEN\/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer. Cancer Res. 2015;75:415\u201325.","journal-title":"Cancer Res"},{"key":"8657_CR16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/carcin\/bgw058","volume":"37","author":"AL Parker","year":"2016","unstructured":"Parker AL, Turner N, McCarroll JA, Kavallaris M. \u03b2III-Tubulin alters glucose metabolism and stress response signaling to promote cell survival and proliferation in glucose-starved non-small cell lung cancer cells. Carcinogenesis. 2016;37:787\u201398.","journal-title":"Carcinogenesis"},{"key":"8657_CR17","doi-asserted-by":"publisher","first-page":"34395","DOI":"10.18632\/oncotarget.9118","volume":"7","author":"MB Aldonza","year":"2016","unstructured":"Aldonza MB, Hong JY, Alinsug MV, Song J, Lee SK. Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation. Oncotarget. 2016;7:34395\u2013419.","journal-title":"Oncotarget"},{"key":"8657_CR18","doi-asserted-by":"publisher","first-page":"9356","DOI":"10.1158\/0008-5472.CAN-07-0509","volume":"67","author":"PP Gan","year":"2007","unstructured":"Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 2007;67:9356\u201363.","journal-title":"Cancer Res"},{"key":"8657_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1517\/14728222.2013.766170","volume":"17","author":"R Karki","year":"2013","unstructured":"Karki R, Mariani M, Andreoli M, He S, Scambia G, Shahabi S, et al. betaIII-Tubulin: biomarker of taxane resistance or drug target?. Expert Opin Ther Targets. 2013;17:461\u201372.","journal-title":"Expert Opin Ther Targets"},{"key":"8657_CR20","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1158\/0008-5472.CAN-09-4487","volume":"70","author":"JA McCarroll","year":"2010","unstructured":"McCarroll JA, Gan PP, Liu M, Kavallaris M. betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res. 2010;70:4995\u20135003.","journal-title":"Cancer Res"},{"key":"8657_CR21","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/1535-7163.MCT-14-0950","volume":"14","author":"D Kanojia","year":"2015","unstructured":"Kanojia D, Morshed RA, Zhang L, Miska JM, Qiao J, Kim JW, et al. betaiii-tubulin regulates breast cancer metastases to the brain. Mol Cancer Ther. 2015;14:1152\u201361.","journal-title":"Mol Cancer Ther"},{"key":"8657_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41580-023-00689-6","volume":"25","author":"J Yuan","year":"2024","unstructured":"Yuan J, Ofengeim D. A guide to cell death pathways. Nat Rev Mol Cell Biol. 2024;25:379\u201395.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8657_CR23","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1021\/acs.biomac.6b00185","volume":"17","author":"J Teo","year":"2016","unstructured":"Teo J, McCarroll JA, Boyer C, Youkhana J, Sagnella SM, Duong HT, et al. A rationally optimized nanoparticle system for the delivery of RNA interference therapeutics into pancreatic tumors in vivo. Biomacromolecules. 2016;17:2337\u201351.","journal-title":"Biomacromolecules"},{"key":"8657_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81299-0","volume":"11","author":"J Kokkinos","year":"2021","unstructured":"Kokkinos J, Sharbeen G, Haghighi KS, Ignacio RMC, Kopecky C, Gonzales-Aloy E, et al. Ex vivo culture of intact human patient derived pancreatic tumour tissue. Sci Rep. 2021;11:1944.","journal-title":"Sci Rep"},{"key":"8657_CR25","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.cell.2019.02.001","volume":"176","author":"L Pan","year":"2019","unstructured":"Pan L, Fu TM, Zhao W, Zhao L, Chen W, Qiu C, et al. Higher-order clustering of the transmembrane anchor of DR5 drives signaling. Cell. 2019;176:1477\u20131489.e1414.","journal-title":"Cell"},{"key":"8657_CR26","doi-asserted-by":"publisher","first-page":"36804","DOI":"10.18632\/oncotarget.26407","volume":"9","author":"JD Twomey","year":"2018","unstructured":"Twomey JD, Zhao L, Luo S, Xu Q, Zhang B. Tubulin couples death receptor 5 to regulate apoptosis. Oncotarget. 2018;9:36804\u201315.","journal-title":"Oncotarget"},{"key":"8657_CR27","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1038\/ncb1933","volume":"11","author":"S Tonzani","year":"2009","unstructured":"Tonzani S. TIRF: imaging at the cellular edge. Nat Cell Biol. 2009;11:S16\u2013S16.","journal-title":"Nat Cell Biol"},{"key":"8657_CR28","doi-asserted-by":"crossref","unstructured":"Kretz AL, von Karstedt S, Hillenbrand A, Henne-Bruns D, Knippschild U, Trauzold A, et al. Should we keep walking along the trail for pancreatic cancer treatment? Revisiting TNF-related apoptosis-inducing ligand for anticancer therapy. Cancers. 2018;10:77.","DOI":"10.3390\/cancers10030077"},{"key":"8657_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495\u2013516.","journal-title":"Toxicol Pathol"},{"key":"8657_CR30","doi-asserted-by":"publisher","first-page":"7046","DOI":"10.1128\/MCB.00520-06","volume":"26","author":"D Merino","year":"2006","unstructured":"Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006;26:7046\u201355.","journal-title":"Mol Cell Biol"},{"key":"8657_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/cdd.2015.174","volume":"23","author":"D de Miguel","year":"2016","unstructured":"de Miguel D, Lemke J, Anel A, Walczak H, Martinez-Lostao L. Onto better TRAILs for cancer treatment. Cell Death Differ. 2016;23:733\u201347.","journal-title":"Cell Death Differ"},{"key":"8657_CR32","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1158\/0008-5472.CAN-20-2496","volume":"81","author":"G Sharbeen","year":"2021","unstructured":"Sharbeen G, McCarroll JA, Akerman A, Kopecky C, Youkhana J, Kokkinos J, et al. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to SLC7A11 inhibition. Cancer Res. 2021;81:3461\u201379.","journal-title":"Cancer Res"},{"key":"8657_CR33","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/MPA.0000000000002032","volume":"51","author":"A Kato","year":"2022","unstructured":"Kato A, Naitoh I, Naiki-Ito A, Hayashi K, Okumura F, Fujita Y, et al. Class III \u03b2-tubulin expression is of value in selecting nab -paclitaxel and gemcitabine as first-line therapy in unresectable pancreatic cancer. Pancreas. 2022;51:372\u20139.","journal-title":"Pancreas"},{"key":"8657_CR34","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9:1102\u201323.","journal-title":"Cancer Discov"},{"key":"8657_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214:579\u201396.","journal-title":"J Exp Med"},{"key":"8657_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10968-6","volume":"10","author":"C Vennin","year":"2019","unstructured":"Vennin C, Melenec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, et al. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nat Commun. 2019;10:3637.","journal-title":"Nat Commun"},{"key":"8657_CR37","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.it.2016.06.002","volume":"37","author":"AT Ting","year":"2016","unstructured":"Ting AT, Bertrand MJM. More to Life than NF-kappaB in TNFR1 signaling. Trends Immunol. 2016;37:535\u201345.","journal-title":"Trends Immunol"},{"key":"8657_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"8657_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109291","volume":"35","author":"AM Waters","year":"2021","unstructured":"Waters AM, Khatib TO, Papke B, Goodwin CM, Hobbs GA, Diehl JN, et al. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Rep. 2021;35:109291.","journal-title":"Cell Rep"},{"key":"8657_CR40","first-page":"695","volume":"40","author":"M Shibazaki","year":"2012","unstructured":"Shibazaki M, Maesawa C, Akasaka K, Kasai S, Yasuhira S, Kanno K, et al. Transcriptional and post-transcriptional regulation of betaIII-tubulin protein expression in relation with cell cycle-dependent regulation of tumor cells. Int J Oncol. 2012;40:695\u2013702.","journal-title":"Int J Oncol"},{"key":"8657_CR41","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s13277-015-4058-y","volume":"37","author":"M Xiao","year":"2016","unstructured":"Xiao M, Tang Y, Chen WW, Wang YL, Yang L, Li X, et al. Tubb3 regulation by the Erk and Akt signaling pathways: a mechanism involved in the effect of arginine ADP-ribosyltransferase 1 (Art1) on apoptosis of colon carcinoma CT26 cells. Tumour Biol J Int Soc Oncodev Biol Med. 2016;37:2353\u201363.","journal-title":"Tumour Biol J Int Soc Oncodev Biol Med"},{"key":"8657_CR42","first-page":"1583","volume":"9","author":"G Chen","year":"2019","unstructured":"Chen G, Sun L, Han J, Shi S, Dai Y, Liu W. RILPL2 regulates breast cancer proliferation, metastasis, and chemoresistance via the TUBB3\/PTEN pathway. Am J Cancer Res. 2019;9:1583\u2013606.","journal-title":"Am J Cancer Res"},{"key":"8657_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.gene.2014.03.037","volume":"542","author":"G Raspaglio","year":"2014","unstructured":"Raspaglio G, Petrillo M, Martinelli E, Li Puma DD, Mariani M, De Donato M, et al. Sox9 and Hif-2\u03b1 regulate TUBB3 gene expression and affect ovarian cancer aggressiveness. Gene. 2014;542:173\u201381.","journal-title":"Gene"},{"key":"8657_CR44","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.gene.2007.11.015","volume":"409","author":"G Raspaglio","year":"2008","unstructured":"Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, Cicchillitti L, et al. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3\u2019 flanking region. Gene. 2008;409:100\u20138.","journal-title":"Gene"},{"key":"8657_CR45","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.mvr.2011.09.003","volume":"83","author":"PC Stapor","year":"2012","unstructured":"Stapor PC, Murfee WL. Identification of class III \u03b2-tubulin as a marker of angiogenic perivascular cells. Microvasc Res. 2012;83:257\u201362.","journal-title":"Microvasc Res"},{"key":"8657_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4251\/wjgo.v10.i10.351","volume":"10","author":"XQ Kong","year":"2018","unstructured":"Kong XQ, Huang YX, Li JL, Zhang XQ, Peng QQ, Tang LR, et al. Prognostic value of vascular endothelial growth factor receptor 1 and class III \u03b2-tubulin in survival for non-metastatic rectal cancer. World J Gastrointest Oncol. 2018;10:351\u20139.","journal-title":"World J Gastrointest Oncol"},{"key":"8657_CR47","doi-asserted-by":"publisher","first-page":"9216","DOI":"10.18632\/oncotarget.13985","volume":"8","author":"G Sharbeen","year":"2017","unstructured":"Sharbeen G, Youkhana J, Mawson A, McCarroll J, Nunez A, Biankin A, et al. MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. Oncotarget. 2017;8:9216\u201329.","journal-title":"Oncotarget"},{"key":"8657_CR48","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1136\/gutjnl-2017-315144","volume":"67","author":"A Chou","year":"2018","unstructured":"Chou A, Froio D, Nagrial AM, Parkin A, Murphy KJ, Chin VT, et al. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut. 2018;67:2142\u201355.","journal-title":"Gut"},{"key":"8657_CR49","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-07-2477","volume":"68","author":"A Vonlaufen","year":"2008","unstructured":"Vonlaufen A, Joshi S, Qu C, Phillips PA, Xu Z, Parker NR, et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 2008;68:2085\u201393.","journal-title":"Cancer Res"},{"key":"8657_CR50","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0016-5085(98)70209-4","volume":"115","author":"MG Bachem","year":"1998","unstructured":"Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A, et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology. 1998;115:421\u201332.","journal-title":"Gastroenterology"},{"key":"8657_CR51","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/gut.43.1.128","volume":"43","author":"MV Apte","year":"1998","unstructured":"Apte MV, Haber PS, Applegate TL, Norton ID, McCaughan GW, Korsten MA, et al. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut. 1998;43:128\u201333.","journal-title":"Gut"},{"key":"8657_CR52","doi-asserted-by":"publisher","first-page":"e0127386","DOI":"10.1371\/journal.pone.0127386","volume":"10","author":"M Zhang","year":"2015","unstructured":"Zhang M, Harashima N, Moritani T, Huang W, Harada M. The roles of ROS and caspases in TRAIL-induced apoptosis and necroptosis in human pancreatic cancer cells. PLoS ONE. 2015;10:e0127386.","journal-title":"PLoS ONE"},{"key":"8657_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep"},{"key":"8657_CR54","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1085\/jgp.201812143","volume":"151","author":"A Abu-Arish","year":"2019","unstructured":"Abu-Arish A, Pand\u017ei\u0107 E, Kim D, Tseng HW, Wiseman PW, Hanrahan JW. Agonists that stimulate secretion promote the recruitment of CFTR into membrane lipid microdomains. J Gen Physiol. 2019;151:834\u201349.","journal-title":"J Gen Physiol"},{"key":"8657_CR55","doi-asserted-by":"crossref","unstructured":"Abu-Arish A, Pand\u017ei\u0107 E, Luo Y, Sato Y, Turner MJ, Wiseman PW, et al. Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs. J Cell Sci. 2022;135:jcs259002.","DOI":"10.1242\/jcs.259002"},{"key":"8657_CR56","doi-asserted-by":"crossref","unstructured":"Pand\u017ei\u0107 E, Hanrahan JW, Abu-Arish A, Wiseman PW. Measurement of Protein Transport in Heterogeneous Environments Using Confinement k-Space Image Correlation Spectroscopy. Biomolecules. 2026;16:519.","DOI":"10.3390\/biom16040519"},{"key":"8657_CR57","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.2009.25.4847","volume":"28","author":"JC Soria","year":"2010","unstructured":"Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, et al. Phase 1b study of dulanermin (recombinant human Apo2L\/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol. 2010;28:1527\u201333.","journal-title":"J Clin Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08657-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08657-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08657-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:02:19Z","timestamp":1780891339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08657-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8657"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08657-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"547"}}